

CLAIMS

1. A pharmaceutically acceptable crystalline addition salt which is one of
- 5 *trans*-4-((3-(2-chloro-4-(((2*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)methyl)-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)-cyclohexyl hydroxy(di-2-thienyl)acetate ethanedisulfonate,
- 10 *trans*-4-((2-(2-chloro-4-(((*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)-methyl)-5-methoxyphenylcarbamoyloxy)ethyl)-(methyl)amino)-cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate disaccharinate, and
- 15 *trans*-4-((2-(2-chloro-4-(((*R*)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino)-methyl)-5-methoxyphenylcarbamoyloxy)ethyl)-(methyl)amino)cyclohexyl 2-hydroxy-2,2-di(thiophen-2-yl)acetate L-tartrate, or a pharmaceutically acceptable solvate thereof.
2. A pharmaceutical composition comprising a therapeutically effective amount of a salt as defined in claim 1 and a pharmaceutically
- 20 acceptable carrier.
3. A pharmaceutical composition according to claim 2, which is formulated for administration by inhalation as a dry powder.
- 25 4. A pharmaceutical composition according to claim 2 or 3, which further comprises a therapeutically effective amount of one or more other therapeutic agents.
5. A pharmaceutical composition according to claim 4 wherein the
- 30 other therapeutic agent is selected from:
- (a) corticosteroids, or glucocorticoids,
 - (b) antihistamines,

- (c) chemokine receptor antagonists, such as maraviroc or enfuvirtide,
- (e) CRth2 antagonists,
- (f) leukotriene receptor antagonists,
- (g) JAK inhibitors such as tofacitinib or INCB018424,
- 5 (h) Syk inhibitors such as R-343,
- (i) phosphodiesterase IV inhibitors,
- (j) p38 Inhibitors such as ARRY-797,
- (k) PKC inhibitors such as NVP-AEB071,
- (l) 5-lipoxygenase activating protein inhibitors, such as veliflapon,
- 10 (m) 5-lipoxygenase inhibitors,
- (n) CYSLTR1 antagonists,
- (o) CYSLTR2 antagonists,
- (p) BLT1 antagonists,
- (q) BLT2 antagonists,
- 15 (r) thromboxane A2 antagonists such as ramatroban,
- (s) DP1 receptor antagonists, such as laropiprant,
- (t) DP1 receptor agonists, such as BW-245C,
- (u) IP receptor agonists, such as RO-1138452,
- (v) Anti-IgE, such as omalizumab,
- 20 (w) IL5 antibody, such as mepolizumab,
- (x) leukotriene formation inhibitors,
- (y) decongestants, such as ephedrine, levo-methamphetamine, naphazoline, oxymetazoline, phenylephrine, phenylpropanolamine, propylhexedrine, pseudoephedrine, synephrine or tetrahydrozoline;
- 25 (z) mucolytics such as acetylcysteine, ambroxol, bromhexine, carbocisteine, domiodol, eprazinone, erdosteine, letosteine, nelteneine, sobrerol, stepronin or tiopronin;
- (aa) antitussives, such as dextromethorphan,
- (bb) analgesics such as aspirin, paracetamol, rofecoxid, celecoxib,
- 30 morphine, codeine, oxycodone, hydrocodone, dihydromorphine or flupirtine; and

(cc) expectorants such antimony pentasulfide, guaiacolsulfonate, guaifenesin, potassium iodide or tyloxapol.

6. A combination comprising a salt as defined in claim 1 and one or
5 more other therapeutic agents as defined in claim 5.

7. A salt according to claim 1, a pharmaceutical composition as defined in any one of claims 2 to 5 or a combination as defined in claim 6, for use in the treatment of a pathological condition or disease associated with both
10 β 2 adrenergic receptor and M3 antimuscarinic activity, wherein the pathological condition or disease is asthma, acute or chronic bronchitis, emphysema, or Chronic Obstructive Pulmonary Disease (COPD).

8. A salt, pharmaceutical composition or combination for use as
15 defined in claim 7, wherein the pathological condition or disease is asthma or chronic obstructive pulmonary disease.